Skip to content

Public FDA record

Z-2362-2019: Roche Elecsys Anti-CCP Immunoassay Catalog # 05031656160

Recall record Z-2362-2019 for Roche Diagnostics Operations, Inc.. View source facts, labeled dates, and the original FDA record.

FDA identifier
Z-2362-2019
Company in FDA record
Roche Diagnostics Operations, Inc.
FDA classification date
Aug 23, 2019
First observed by MedTech Watch
Nov 16, 2026
Latest observed content change
Nov 16, 2026
Recall classification
Class II

Reason stated in the source

Performance issues with certain lots of the Elecsys Anti-CCP assay on the cobas e 411 analyzer; MODULAR ANALYTICS E 170 module; and cobas e 601, 602, and 801 modules with plasma samples.

Source facts

Action
Customers will be instructed to only use serum samples when testing with one of the affected lots numbers. Re-measure the sample if an implausible result occurs while using plasma samples, and a high Anti-CCP result does not match the patients clinical picture. To follow the work-around provided in the UMDC concerning pre-analytical sample handling for plasma samples. Perform maintenance according to the operator manual (e.g., Liquid Flow Cleaning [LFC]) to ensure proper functioning of the analyzer or module. Customers will be reminded that sample quality can be affected by fibrin clots and how this significantly impacts the Anti-CCP results. Please contact the Roche Support Network Customer Support Center, 24 hours a day, seven days a week at 1-800-428-2336 if you have questions about the information contained in this UMDC. ***Updated 7/17/20*** An updated letter was sent out to customers on July 13, 2020. After further investigation, Roche has decided to remove human plasma as a sample type from the intended use and remove all claims associated with the plasma sample type. The change is applicable for all current and upcoming lots. Customer actions required: " Use the Elecsys Anti-CCP assay with serum samples only for all current and future Elecsys Anti-CCP lot numbers. " ALL customers, complete the response form included with the letter and return to the firm " If you cannot run serum samples in your laboratory, complete the Product Information section of the response form to obtain reagent credit or contact your Roche sales representative for further options. " If your facility has distributed the affected product to another site, please ensure this UMDC is provided to that site. " File this UMDC for future reference. " Discard Urgent Medical Device Correction TP-00714 if you previously received it.
Initiated
2019-07-16
Root cause
Under Investigation by firm
Terminated
2021-04-30
Distribution
AZ CA FL HI IA IL IN KY LA MA MI MO MT NJ NY OK OR PA PR SC TX VA
Recall number
Z-2362-2019
Recall status
Terminated
CDRH record ID
175149
FDA classified
2019-08-23
Recall event number
83416

Source facts and excerpts are reproduced for research. Dates retain their source meanings. “First observed” describes collection, not FDA publication or product launch.

Recall classification is supplied only when the recall number matches an enforcement record. Recall class and device class are different fields. Several recall records may belong to one recall event.

Useful context

Device classifications

FDA dataset:

Last successful check: Nov 22, 2026

Source classifications may change.

510(k) clearances

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset monthly.

Recall records

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset weekly.

Keep this research moving.

Follow ten competitors and ten product codes. Get matching changes in your dashboard and a weekly brief, for $49/month.

Start a 14-day free trial ↗